Renaissance Capital logo

Zhengye Biotechnology Holding Filed Terms, Nasdaq: ZYBT

Chinese provider of veterinary vaccines with a focus on livestock.

Industry: Health Care

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Health Care

Our mission is to become a world-leading manufacturer of veterinary vaccines and to provide reliable veterinary vaccines to the world. We, through the operating entity, focus on the research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. For nearly 20 years, the operating entity has been committed to enhancing the health of animals. The operating entity markets a diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The operating entity’s products are available in 29 provincial regions across China and are exported overseas to Vietnam, Pakistan and Egypt. The operating entity currently owns 43 veterinary vaccines in its product portfolio, which cover major veterinary vaccines for livestock, including monovalent vaccine, polyvalent vaccine, combined vaccine and combined and polyvalent vaccine. The operating entity has built three veterinary vaccine production floors, including 13 vaccine production lines, one quality examination center, and one animal facility for vaccine development, all operating in accordance with Good Manufacturing Practices for Veterinary Drugs issued by the Ministry of Agriculture and Rural Affairs of the PRC.
more less
IPO Data
IPO File Date 01/09/2024
Offer Price
Price Range $4.00 - $5.00
Offer Shares (mm) 1.5
Deal Size ($mm) $7
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date
Offer Price
Price Range $4.00 - $5.00
Offer Shares (mm) 1.5
Deal Size ($mm) $7
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Kingswood Capital Markets
Company Data
Headquarters Jilin, China
Founded 2004
Employees at IPO 299
Website www.jlzybio.com

Zhengye Biotechnology Holding (ZYBT) Performance